For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Growth Hormone Secretagogues

GHRP-2

Also known as: Growth Hormone Releasing Peptide-2

GHRP-2 (pralmorelin) is a synthetic hexapeptide ghrelin receptor agonist that stimulates pituitary growth hormone release. It is approved in Japan (Kaken Pharmaceutical, 2004) as a single-dose diagnostic agent for GH deficiency, but is NOT FDA-approved in the US and is research-only. Unlike ipamorelin, GHRP-2 is non-selective and modestly raises ACTH, cortisol, and prolactin.

Where to buy · live market data

Who's worth your money for GHRP-2

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (98) of 8 scored sellers

$3.20/mg

$16.00 · 5mg · 99.3% purity

Best value

Lowest $/mg among scored sellers

$2.07/mg

$22.99 · 11.13mg · 99.4% purity

Most tested

2 independent COAs on file

$4.60/mg

$46.00 · 10mg · 98.2% purity

Average price

$3.67/mg

Sellers

23

45-day trend

-21.3%

16 of 23 sellers have a current price· 2 stale hidden· 6 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch GHRP-2

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About GHRP-2

CAS

158861-67-7

Molecular formula

C45H55N9O6

Sequence

AAWFK

Typical dose range

100–300 mcg per injection, 2–3x daily, subcutaneous

Half-life

~15–30 minutes

Independent evidence

COAs for GHRP-2

24 third-party tests across 10 vendors. Each card links to the full report.

All 24 COAs for GHRP-2 →
Measured purity 98.0%–99.9% across 16 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.12 %
Jun 2026
ILS Labs Strong

For

GHRP-2

by Ion Peptide· batch G25-06092026

✓ Vendor-published
99.12 %
Jun 2026
ILS Laboratories

For

GHRP-2

by Ion Peptide· batch G25-06092026

COA on file
Aggregated · 3rd-party listing
98.05 %
Apr 2026
Vanguard Laboratory Strong

For

GHRP-2

by Moglabs· batch GH202

Aggregated · 3rd-party listing
99.43 %
Mar 2026
Freedom Diagnostics Moderate · HPLC

For

GHRP-2

by Simple Peptide· batch GHRP2-100032026-1

Aggregated · 3rd-party listing
99.03 %
Mar 2026
Vanguard Laboratory Strong

For

GHRP-2

by Peptidology· batch 1672

Aggregated · 3rd-party listing
99.94 %
Feb 2026
Freedom Diagnostics Moderate · HPLC

For

GHRP-2

by Simple Peptide· batch GHRP2-022026

Aggregated · 3rd-party listing
99.38 %
Feb 2026
Freedom Diagnostics Moderate

For

GHRP-2

by Modern Research Peptides· batch G210261

✓ Vendor-published
99.70 %
Feb 2026
Analytical Formulations, Inc.

For

GHRP-2

by Ion Peptide· batch GHP25-01272026

COA on file
✓ Vendor-published
99.75 %
Dec 2025
Freedom Diagnostics Moderate

For

GHRP-2

by Ion Peptide· batch GH2-5-122825

COA on file
Aggregated · 3rd-party listing
99.75 %
Dec 2025
Freedom Diagnostics Moderate

For

GHRP-2

by Ion Peptide· batch GH2-S-122825

Aggregated · 3rd-party listing
99.28 %
Nov 2025
Janoshik Analytical Limited

For

GHRP-2

by Moglabs· batch hg2001

✓ Vendor-published
99.28 %
Nov 2025
Janoshik Analytical Limited

For

GHRP-2

by Moglabs· batch hg2001

COA on file
✓ Vendor-published
99.28 %
Nov 2025
Janoshik Analytical Limited

For

GHRP-2

by Ruo Bio· batch hg2001

COA on file
Aggregated · 3rd-party listing
99.63 %
Jun 2025
Vanguard Laboratory Strong

For

GHRP-2

by Kimera Chems· batch White Cap

Aggregated · 3rd-party listing
99.29 %
Nov 2024
Chromate Moderate

For

GHRP-2

by Soma Peptides· batch GHX102401

Aggregated · 3rd-party listing
99.37 %
Jul 2024
Janoshik Analytical Limited · HPLC

For

GHRP-2

by Peptide Tech· batch G2-001

Aggregated · 3rd-party listing
99.75 %
Analytical Formulations, Inc.

For

GHRP-2

by Ion Peptide· batch GHP25-01272026

Aggregated · 3rd-party listing
99.41 %
Kovera Labs

For

GHRP-2 Acetate

by Real Peptides· batch RP052226

Aggregated · 3rd-party listing
98.78 %
Kovera Labs

For

GHRP-2

by Real Peptides· batch BATCH-0322

Aggregated · 3rd-party listing
98.16 %
Vanguard Laboratory Strong

For

GHRP-2

by Certified Peptides· batch GHRP2070726

✓ Vendor-published
—
Aug 2026

Purity not on file

Janoshik Analytical Limited

For

GHRP-2

by Verified Peptides· batch G208260610F

COA on file
Aggregated · 3rd-party listing
—

Purity not on file

Vanguard Laboratory Strong

For

GHRP-2

by Certified Peptides· batch GHRP21025

✓ Vendor-published
—

Purity not on file

Lab unknown

For

GHRP-2

by Ruo Bio

COA on file
✓ Vendor-published
—

Purity not on file

Lab unknown

For

GHRP-2

by Moglabs

COA on file
Research depth

12 citations indexed for GHRP-2

All research on GHRP-2 →

Study · 2026

Differentiating hypothalamic from pituitary adrenal insufficiency: underlying causes and diagnostic utility of the corticotropin-releasing hormone and growth hormone-releasing peptide-2 stimulation tests

In Japan, the Corticotropin-releasing hormone (CRH) stimulation test is widely used to evaluate secondary adrenal insufficiency (SAI); however, the insulin tolerance test (ITT) is sometimes required to assess hypothalamic dysfunction.

Study · 2026

Chronic Central Adrenal Insufficiency in a Patient With Remote Traumatic Brain Injury and an Apparently Adequate Standard-Dose ACTH Response: A Case Report

In patients with a remote history of traumatic brain injury, central adrenal insufficiency may remain unrecognized for decades.

case-report · 2026

Reversible predominant thyrotropin axis dysfunction with meningitis in suspected lymphocytic hypophysitis

Lymphocytic hypophysitis (LYH), attributed to autoimmune mechanisms, typically causes multiple anterior pituitary hormone deficiencies, with corticotroph dysfunction occurring earliest; predominant thyrotroph dysfunction is uncommon. A 65-year-old woman presented with headache, fever, and diplopia.

case-report · 2026

Coexisting mild autonomous cortisol secretion and isolated adrenocorticotropic hormone deficiency in a patient with an adrenal incidentaloma

Low adrenocorticotropic hormone (ACTH) in a patient with an adrenal incidentaloma is usually attributed to ACTH-independent cortisol secretion. A 71-year-old woman with a 20-mm left adrenal mass had no cushingoid features.

Study · 2026

Growth Hormone-Releasing Peptides: Investigation of Their Secondary Structure, Thermal Stability, and Model Membrane Interactions

Growth hormone-releasing peptides (GHRPs) comprise a group of small synthetic peptides that can effectively influence growth hormone secretion both in humans and animals.

case-report · 2026

Differential reversibility of anterior and posterior pituitary dysfunction in delayed recurrent pediatric Rathke's cleft cyst

Summary Rathke's cleft cyst (RCC) is a benign sellar or suprasellar lesion increasingly detected by magnetic resonance imaging (MRI).